Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, are effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is limited by the development of resistance in part explained by the gain of a secondary EGFR mutation, T790M, at the ga...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ercan, Dalia, Zejnullahu, Kreshnik, Yonesaka, Kimio, Xiao, Yun, Capelletti, Marzia, Rogers, Andrew, Lifshits, Eugene, Brown, Alison, Lee, Charles, Christensen, James G., Kwiatkowski, David J., Engelman, Jeffrey A., Jänne, Pasi A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2859699/
https://ncbi.nlm.nih.gov/pubmed/20118985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2009.526
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares